The post USD/JPY steadies above 147.20 as US tariffs ruled illegal appeared on BitcoinEthereumNews.com. USD/JPY posts minimal gains after August’s 2.4% drop, trading at 147.28 amid thin holiday volumes. US appeals court ruled Trump’s tariffs illegal, but duties remain as case heads toward Supreme Court. Traders price 90% chance of September Fed cut: BoJ rate hike odds steady at 50% amid soft inflation. The USD/JPY posted minimal gains on Monday after losing over 2.40% in August amid thin trading, with US markets closed in observance of Labor Day. The pair trades at 147.28 as the Greenback continues to weaken amid news that the US Court of Appeals has ruled Trump’s tariffs illegal. Dollar weakens despite court ruling on Trump tariffs; traders await ISM PMI and critical Nonfarm Payrolls Despite its decision, the US federal court kept tariffs in place as the fight escalated to the US Supreme Court. The status of Trump’s early agreements with Japan and South Korea is unclear, as the imposed duties were deemed illegal. Nevertheless, most analysts agreed that the court’s decision will not mark the end of the trade war. Aside from this, traders await the release of the ISM Manufacturing PMI over the week, along with a crucial Nonfarm Payrolls report, which could cement the case for an interest rate cut by the Federal Reserve. Money market futures had priced in a 90% chance that the Fed Chair Jerome Powell and Co. would reduce rates by 25 basis points, according to the Prime Market Terminal (PMT) interest rate probabilities tool. On the Japanese front, the lack of Tier 1 releases and trade uncertainty between the US and Japan are weighing on the Japanese Yen as the top trade negotiator postponed his trip to the US due to a disagreement regarding rice purchases. Last week, Tokyo’s core inflation fell to 2.5% in August from 2.9%, matching estimates. The BoJ’s… The post USD/JPY steadies above 147.20 as US tariffs ruled illegal appeared on BitcoinEthereumNews.com. USD/JPY posts minimal gains after August’s 2.4% drop, trading at 147.28 amid thin holiday volumes. US appeals court ruled Trump’s tariffs illegal, but duties remain as case heads toward Supreme Court. Traders price 90% chance of September Fed cut: BoJ rate hike odds steady at 50% amid soft inflation. The USD/JPY posted minimal gains on Monday after losing over 2.40% in August amid thin trading, with US markets closed in observance of Labor Day. The pair trades at 147.28 as the Greenback continues to weaken amid news that the US Court of Appeals has ruled Trump’s tariffs illegal. Dollar weakens despite court ruling on Trump tariffs; traders await ISM PMI and critical Nonfarm Payrolls Despite its decision, the US federal court kept tariffs in place as the fight escalated to the US Supreme Court. The status of Trump’s early agreements with Japan and South Korea is unclear, as the imposed duties were deemed illegal. Nevertheless, most analysts agreed that the court’s decision will not mark the end of the trade war. Aside from this, traders await the release of the ISM Manufacturing PMI over the week, along with a crucial Nonfarm Payrolls report, which could cement the case for an interest rate cut by the Federal Reserve. Money market futures had priced in a 90% chance that the Fed Chair Jerome Powell and Co. would reduce rates by 25 basis points, according to the Prime Market Terminal (PMT) interest rate probabilities tool. On the Japanese front, the lack of Tier 1 releases and trade uncertainty between the US and Japan are weighing on the Japanese Yen as the top trade negotiator postponed his trip to the US due to a disagreement regarding rice purchases. Last week, Tokyo’s core inflation fell to 2.5% in August from 2.9%, matching estimates. The BoJ’s…

USD/JPY steadies above 147.20 as US tariffs ruled illegal

2025/09/02 21:37
  • USD/JPY posts minimal gains after August’s 2.4% drop, trading at 147.28 amid thin holiday volumes.
  • US appeals court ruled Trump’s tariffs illegal, but duties remain as case heads toward Supreme Court.
  • Traders price 90% chance of September Fed cut: BoJ rate hike odds steady at 50% amid soft inflation.

The USD/JPY posted minimal gains on Monday after losing over 2.40% in August amid thin trading, with US markets closed in observance of Labor Day. The pair trades at 147.28 as the Greenback continues to weaken amid news that the US Court of Appeals has ruled Trump’s tariffs illegal.

Dollar weakens despite court ruling on Trump tariffs; traders await ISM PMI and critical Nonfarm Payrolls

Despite its decision, the US federal court kept tariffs in place as the fight escalated to the US Supreme Court. The status of Trump’s early agreements with Japan and South Korea is unclear, as the imposed duties were deemed illegal. Nevertheless, most analysts agreed that the court’s decision will not mark the end of the trade war.

Aside from this, traders await the release of the ISM Manufacturing PMI over the week, along with a crucial Nonfarm Payrolls report, which could cement the case for an interest rate cut by the Federal Reserve.

Money market futures had priced in a 90% chance that the Fed Chair Jerome Powell and Co. would reduce rates by 25 basis points, according to the Prime Market Terminal (PMT) interest rate probabilities tool.

On the Japanese front, the lack of Tier 1 releases and trade uncertainty between the US and Japan are weighing on the Japanese Yen as the top trade negotiator postponed his trip to the US due to a disagreement regarding rice purchases.

Last week, Tokyo’s core inflation fell to 2.5% in August from 2.9%, matching estimates. The BoJ’s rate hike odds stand at 50%, according to the PMT tool.

USD/JPY Price Forecast: Terminal outlook

The USD/JPY daily chart suggests the pair might continue to consolidate, within the 146.66 – 148.18 range, unless a fresh catalyst —which could be NFP data— could trigger a breach below/above the boundaries set by traders.

If the pair climbs past 148.00, the first resistance would be August’s 27 high of 148.18. Once cleared, the next area of interest would be the 200-day Simple Moving Average (SMA) at 148.85 ahead of 149.00. On the other hand, a drop below the 50-day SMA at 147.00 will expose the August 28 low of 146.66, followed by August’s monthly low of 146.21.

Japanese Yen Price Last 30 days

The table below shows the percentage change of Japanese Yen (JPY) against listed major currencies last 30 days. Japanese Yen was the strongest against the US Dollar.

USDEURGBPJPYCADAUDNZDCHF
USD-2.38%-2.49%-2.30%-0.64%-1.86%0.00%-1.36%
EUR2.38%-0.02%0.10%1.85%0.66%2.30%1.11%
GBP2.49%0.02%0.14%1.87%0.68%2.54%1.15%
JPY2.30%-0.10%-0.14%1.68%0.44%2.24%0.96%
CAD0.64%-1.85%-1.87%-1.68%-1.25%0.66%-0.70%
AUD1.86%-0.66%-0.68%-0.44%1.25%1.84%0.59%
NZD-0.01%-2.30%-2.54%-2.24%-0.66%-1.84%-1.25%
CHF1.36%-1.11%-1.15%-0.96%0.70%-0.59%1.25%

The heat map shows percentage changes of major currencies against each other. The base currency is picked from the left column, while the quote currency is picked from the top row. For example, if you pick the Japanese Yen from the left column and move along the horizontal line to the US Dollar, the percentage change displayed in the box will represent JPY (base)/USD (quote).

Source: https://www.fxstreet.com/news/usd-jpy-steadies-above-14720-as-us-tariffs-ruled-illegal-202509011545

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Share Insights

You May Also Like

New Viral Presale on XRPL: DeXRP Surpassed $6.4 Million

New Viral Presale on XRPL: DeXRP Surpassed $6.4 Million

The post New Viral Presale on XRPL: DeXRP Surpassed $6.4 Million  appeared on BitcoinEthereumNews.com. One of the most talked-about ecosystems in the cryptocurrency space is the XRP Ledger (XRPL), and DeXRP, the first Presale on XRPL, recently made headlines for its growth story. Attracting over 9,300 investors globally, the project has now raised over $6.4 million and is rapidly emerging as one of the most viral cryptocurrency launches of 2025. By integrating AMM and Order Book trading with a cutting-edge LP system and an open voting process for holders, DeXRP hopes to establish itself as the preferred trading destination for the XRPL community. What is DeXRP?  As the first decentralized exchange (DEX) based on XRPL, DeXRP is taking center stage as XRP continues to solidify its place in the global market. Massive expectation has been generated by the combination of DeXRP’s ambition for an advanced trading platform and XRPL’s established infrastructure, which is renowned for its quick transactions, cheap fees, and institutional-ready capabilities. In contrast to a lot of speculative presales, DeXRP’s development shows both institutional interest and community-driven momentum. Its early achievement of the $6.4 million milestone demonstrates how rapidly investors are realizing its potential. DeXRP Presale Success More than 9,300 distinct wallets have already joined the DeXRP presale, indicating a high level of interest from around the world. A crucial aspect is highlighted by the volume and variety of participation: DeXRP is not merely a niche project; rather, it is emerging as a major force in the XRPL ecosystem. DeXRP’s recent collaborations with WOW Earn and Micro3, as well as its sponsorship of the WOW Summit in Hong Kong, are also contributing factors to this uptick in investor confidence. These actions are blatant attempts to increase the company’s awareness among institutional players and crypto-native groups. The Forbes article summed it up: DeXRP is embedding credibility where others chase hype, marking it as…
Share
2025/09/18 20:14
Share
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
2025/09/18 05:26
Share